a-1331852 and Leukemia--Lymphocytic--Chronic--B-Cell

BH3 mimetics are novel targeted drugs with remarkable specificity, potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to increasing doses of navitoclax (ABT-263), a BH3 mimetic. To mimic such rapid development of chemoresistance, we developed simple resistance models to three different BH3 mimetics, targeting BCL-2 (ABT-199), BCL-X

Topics: Antineoplastic Agents; bcl-X Protein; Benzothiazoles; Biomimetics; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Glutamine; Humans; Indoles; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lipogenesis; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured